Quark Pharmaceuticals

** QUARK is conducting A Dose Escalation Trial of the Safety and Pharmacokinetics of a Single Intravenous Injection in Patients Undergoing Major Cardiovascular Surgery. This study is currently recruiting participants: clinicaltrials.gov

Quark Pharmaceuticals is an evolving pharmaceutical company using rational drug design to develop new therapeutics for unmet medical needs. Our pro...

PF-4523655 (formerly RTP801i-14) is a synthetic, siRNA molecule designed to inhibit the expression of Quark’s proprietary target, RTP...

QPI-1002 (formerly AKIi-5) is an siRNA drug candidate designed to temporarily inhibit the expression of human p53. Its development is...

Development Pipeline...

6/9/2009

Quark Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit

5/14/2009

Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage